

The University of Texas at El Paso

**Institutional Biosafety Committee**

**Appendix A Form**

*Instructions:* Forms need to be completed and submitted via [IRBNet](http://www.irbnet.org/) on the 1st of every month. Submissions entered after the two weeks from the meeting date will be considered for review at the following meeting. Meeting dates are posted on the [IBC website](http://research.utep.edu/Default.aspx?tabid=58993). Any questions contact the IBC office at ibc@utep.edu.

|  |
| --- |
| **A.** **APPENDIX A: Viral Vectors***See also, the NIH guidance document, Biosafety Considerations for Research with viral vectors,* [*https://auth.osp.od.nih.gov/sites/default/files/Lenti\_Containment\_Guidance\_1.pdf*](https://auth.osp.od.nih.gov/sites/default/files/Lenti_Containment_Guidance_1.pdf) |
| **Question:** | **Agent:**       | **Agent:**       | **Agent:**       |

|  |  |  |  |
| --- | --- | --- | --- |
| **A.1 What type of viral vectors will each agent use:** | [ ]  **Lentivirus/ lentivector**[ ]  **Adenoviral Vectors, Adenovirus or Adeno-associated virus/vector**[ ]  **Retroviral vectors or retrovirus****Is it considered replication competent?** [ ]  **NO**  [ ]  **YES** [ ]  **Other virus/vector: Describe:**       | [ ]  **Lentivirus/ lentivector**[ ]  **Adenoviral Vectors, Adenovirus or Adeno-associated virus/vector**[ ]  **Retroviral vectors or retrovirus****Is it considered replication competent?** [ ]  **NO**  [ ]  **YES** [ ]  **Other virus/vector: Describe:**       | [ ]  **Lentivirus/ lentivector**[ ]  **Adenoviral Vectors, Adenovirus or Adeno-associated virus/vector**[ ]  **Retroviral vectors or retrovirus****Is it considered replication competent?** [ ]  **NO**  [ ]  **YES** [ ]  **Other virus/vector: Describe:**       |
| **A.2 How will you acquire the viral vector:** | [ ]  **The viral vector will be produced in my laboratory. List any host systems, helper viruses or packaging cells to be used:**      [ ]  **The viral vector will be obtained from outside supplier/vendor. Provide source:**       | [ ]  **The viral vector will be produced in my laboratory. List any host systems, helper viruses or packaging cells to be used:**      [ ]  **The viral vector will be obtained from outside supplier/vendor. Provide source:**       | [ ]  **The viral vector will be produced in my laboratory. List any host systems, helper viruses or packaging cells to be used:**      [ ]  **The viral vector will be obtained from outside supplier/vendor. Provide source:**       |
| **A.3 Where will the experiments involving the use of viral vectors be performed?** (List all locations applicable and specify building and room number): |       |       |       |
| **A.4 Describe the nature of the vector system and the potential for regeneration of replication competent virus from the vector components.** | Describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk.      | Describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk.      | Describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk.      |
| **A.5 Describe the nature of the transgene insert** (e.g., known oncogenes or genes with high oncogenic potential may merit special care). |       |       |       |
| **A.6 Describe the anticipated vector titer and anticipated total amount of vector to be produced.**  |       |       |       |
| **A.7 Describe the procedure for how the viral vector will be concentrated? Include safety procedure(s) to minimize risk.** |       |       |       |
| **A.8 How many batches will be produced from the original production batch** (more than one batch increases the probability of having a homologous recombination event occur)**?**  |       |       |       |
| **A.9 Describe the inherent biological containment of the animal host, if relevant.** |       |       |       |
| **A.10 Will needles, glassware or other sharps be used while working with risk group 2 organisms?** | [ ]  **NO** [ ]  **YES** If **yes** describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk       | [ ]  **NO** [ ]  **YES** If **yes** describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk       | [ ]  **NO** [ ]  **YES** If **yes** describe what precautions will be taken by the PI and lab personnel to minimize the exposure risk       |
| **A.11** **Describe the potential for insertional mutagenesis in case of accidental needle stick.** |       |       |       |
| **A.12 Provide agents Safety Data Sheet (SDS) and Plasmid Maps if available, upload into IRBNet or with application (Formerly known as Material Safety Data Sheets [MSDS]).**  |